Systema: a framework for evaluating genetic perturbation response prediction beyond systematic variation
Nonparametric baselines We design two nonparametric baselines that we refer to as perturbed mean and matching mean. Perturbed…
Ultima Genomics and Gene by Gene Partner to Expand Global Access to High-Quality, Low-Cost Sequencing on the UG 100™ Platform
Collaboration Extends Global Reach of High-Performance Genomic Sequencing on the UG 100™ Platform FREMONT, Calif. and HOUSTON, Aug.…
Peer perceptions of clinicians using generative AI in medical decision-making
A total of 276 clinicians participated in the study, including 178 physicians, 28 fellows/residents, 60 advanced practice providers…
Leveraging large language models for the deidentification and temporal normalization of sensitive health information in electronic health records
The OpenDeID v2 corpus To evaluate the performance of various machine learning methods and hybrid approaches that combine…
Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
First Breakthrough Therapy Designation in the U.S. for SystImmune and Bristol Myers Squibb’s Izalontamab brengitecan (Iza-bren) based on data…